Stem Cell Therapy Solution, Korea’s Only Ministry of Health and Welfare Certified
MiracellProven Effective in Critical Lower Extremity Ischemia and Cartilage Deficiency Since 2007, Miracell has been conducting collaborative research with domestic and international medical institutions to specialize in safe stem cell therapy. Miracell has dedicated itself to stem cell development, contributing to the nation’s health through advanced medical technology. As a result, Miracell is the only company in Korea to receive New Technology and New Medical Technology certifications from the Ministry of Health and Welfare for stem cell therapy. Miracell’s stem cell solutions have proven to be highly effective in treating bone marrow stem cell-based conditions such as critical lower extremity ischemia, acute myocardial infarction, cartilage defects, and knee osteoarthritis. Since receiving New Medical Technology certification from the Korea Evidence-Based Healthcare Collaborating Agency (NECA) in July 2023, Miracell has been using its bone marrow stem cell products (Smart Mcell, BmSC kit, BSC) at approximately 580 hospitals and clinics in Korea, including large general hospitals such as Severance Hospital, Seoul St. Mary’s Hospital, and Ewha Womans University Mokdong Hospital. The company exports its products to 38 countries. Recently, doctors and stem cell experts from Spain, Dubai, and the Philippines visited Miracell to learn about its treatment techniques and toured its factory. Currently, hospitals in Europe, including Sweden, Austria, Greece, Italy, and Turkey, are importing and using Miracell products. At the “2024 IV CONGRESO SEMDOR VALENCIA” conference, hosted by the Spanish Pain Society on the 25th of last month, Dr. Theodoropoulos Ilias, a hematologist from Greece, presented the results of approximately 400 cases treated directly with Miracell Smart Mcell. Dr. Ilias announced that Miracell stem cell treatment has shown excellent results. Miracell is planning to expand its Miracell production plant in the Osong Industrial Complex to meet the rapidly increasing demand for its products following its new medical technology certification. To achieve this, Miracell is currently pursuing an IPO on the Korea Exchange and plans to quickly raise funds to build a new production facility once the listing is completed. The blueprint for the new plant has been developed and construction permits have been obtained. Miracell is securing core stem cell technology, including domestic and international patent applications for stem cell extraction and treatment technologies. Miracell’s SmartMcell, a stem cell treatment, has completed registration with the US Food and Drug Administration (FDA), and the BmSC kit is also seeking FDA registration. In Europe, both the device (SmartMcell) and the BmSC and BSC kits have received CE certification and are currently exporting. Miracell is leading the global development of stem cell therapy and advanced regenerative medicine.Last May, Miracell was selected as a promising company in the “2024 Global Small and Medium Enterprise 1000+ Project” by the Ministry of SMEs and Startups. With stem cell therapy expanding in the face of a super-aging society, Miracell plans to contribute to improving public health and solidify Korea’s position as a biotechnology powerhouse by promoting Korea’s biotechnology technology globally. [Dong-A Ilbo, Reporter Cho Seon-hee] Source: https://www.donga.com/news/Health/article/all/20241105/130359390/2